CA1050425A - Radioimmunoassay methods for the determination of l-triiodothyronine and thyroxine - Google Patents
Radioimmunoassay methods for the determination of l-triiodothyronine and thyroxineInfo
- Publication number
- CA1050425A CA1050425A CA253,155A CA253155A CA1050425A CA 1050425 A CA1050425 A CA 1050425A CA 253155 A CA253155 A CA 253155A CA 1050425 A CA1050425 A CA 1050425A
- Authority
- CA
- Canada
- Prior art keywords
- thyroxine
- serum
- antiserum
- bound
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 title claims description 74
- 229940034208 thyroxine Drugs 0.000 title claims description 70
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 title claims description 62
- 238000000034 method Methods 0.000 title claims description 58
- 238000003127 radioimmunoassay Methods 0.000 title claims description 48
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 title description 10
- 210000002966 serum Anatomy 0.000 claims description 89
- 230000002285 radioactive effect Effects 0.000 claims description 34
- 239000003153 chemical reaction reagent Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 19
- 238000009739 binding Methods 0.000 claims description 19
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 18
- 229940098773 bovine serum albumin Drugs 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 17
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 15
- 239000003456 ion exchange resin Substances 0.000 claims description 15
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 15
- 230000002163 immunogen Effects 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 13
- 125000003047 N-acetyl group Chemical group 0.000 claims description 12
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 10
- 239000008366 buffered solution Substances 0.000 claims description 10
- 238000011534 incubation Methods 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 238000011067 equilibration Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 claims description 4
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 229940044173 iodine-125 Drugs 0.000 claims description 4
- 239000011369 resultant mixture Substances 0.000 claims description 4
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 claims 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 68
- 239000000243 solution Substances 0.000 description 51
- 229960002319 barbital Drugs 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 24
- 239000011347 resin Substances 0.000 description 23
- 229920005989 resin Polymers 0.000 description 23
- 239000000872 buffer Substances 0.000 description 17
- 238000010790 dilution Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 206010020850 Hyperthyroidism Diseases 0.000 description 13
- 108091006905 Human Serum Albumin Proteins 0.000 description 12
- 102000008100 Human Serum Albumin Human genes 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 10
- IRKGXNAZPUOEMW-UHFFFAOYSA-L magnesium;8-anilinonaphthalene-1-sulfonate Chemical compound [Mg+2].C=12C(S(=O)(=O)[O-])=CC=CC2=CC=CC=1NC1=CC=CC=C1.C=12C(S(=O)(=O)[O-])=CC=CC2=CC=CC=1NC1=CC=CC=C1 IRKGXNAZPUOEMW-UHFFFAOYSA-L 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 238000010998 test method Methods 0.000 description 10
- 241000736355 Euthyroides Species 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 239000011521 glass Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229940075566 naphthalene Drugs 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 235000001055 magnesium Nutrition 0.000 description 7
- 229940091250 magnesium supplement Drugs 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 102000009488 Thyroxine-Binding Proteins Human genes 0.000 description 5
- 108010048889 Thyroxine-Binding Proteins Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- YIFOZCDHLHUIJV-WUJWULDRSA-N (2s)-2,3-dichloro-2-(dichloroamino)-3-[4-(4-hydroxyphenoxy)phenyl]propanoic acid Chemical compound C1=CC(C(Cl)[C@@](Cl)(C(=O)O)N(Cl)Cl)=CC=C1OC1=CC=C(O)C=C1 YIFOZCDHLHUIJV-WUJWULDRSA-N 0.000 description 2
- XUIIKFGFIJCVMT-BNZZDVIVSA-N (2s)-2-amino-3-[4-[4-hydroxy-3,5-bis(iodanyl)phenoxy]-3,5-bis(iodanyl)phenyl]propanoic acid Chemical compound [125I]C1=CC(C[C@H](N)C(O)=O)=CC([125I])=C1OC1=CC([125I])=C(O)C([125I])=C1 XUIIKFGFIJCVMT-BNZZDVIVSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910017974 NH40H Inorganic materials 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- -1 iodo-amino Chemical group 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 229960004025 sodium salicylate Drugs 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ISCMYZGMRHODRP-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCN=C=N ISCMYZGMRHODRP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-M 8-anilinonaphthalene-1-sulfonate Chemical compound C=12C(S(=O)(=O)[O-])=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000428352 Amma Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 1
- 235000013382 Morus laevigata Nutrition 0.000 description 1
- 244000278455 Morus laevigata Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000007982 barbital buffer Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- CEJLBZWIKQJOAT-UHFFFAOYSA-N dichloroisocyanuric acid Chemical compound ClN1C(=O)NC(=O)N(Cl)C1=O CEJLBZWIKQJOAT-UHFFFAOYSA-N 0.000 description 1
- 229940064790 dilantin Drugs 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 210000002320 radius Anatomy 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- FVAUCKIRQBBSSJ-FXMLPJBTSA-M sodium;iodine-125(1-) Chemical compound [Na+].[125I-] FVAUCKIRQBBSSJ-FXMLPJBTSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical group CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000001971 thyroidal effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59067175A | 1975-06-26 | 1975-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1050425A true CA1050425A (en) | 1979-03-13 |
Family
ID=24363198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA253,155A Expired CA1050425A (en) | 1975-06-26 | 1976-05-21 | Radioimmunoassay methods for the determination of l-triiodothyronine and thyroxine |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US4111656A (enExample) |
| JP (1) | JPS584782B2 (enExample) |
| AU (1) | AU500821B2 (enExample) |
| BE (1) | BE843484A (enExample) |
| BR (1) | BR7603472A (enExample) |
| CA (1) | CA1050425A (enExample) |
| DD (1) | DD125022A5 (enExample) |
| DE (1) | DE2627455A1 (enExample) |
| FR (1) | FR2317655A1 (enExample) |
| GB (1) | GB1499958A (enExample) |
| NL (1) | NL7605447A (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7713952A (nl) * | 1977-12-16 | 1979-06-19 | Philips Nv | Radio-immunologische methode voor het bepalen van de schildklierfunktie door een in vitro onderzoek in bloedserum. |
| NL7902396A (nl) * | 1978-04-26 | 1979-10-30 | Abbott Lab | Analyse van galzuren. |
| US4238471A (en) * | 1978-07-12 | 1980-12-09 | Becton, Dickinson And Company | Assay for thyroid hormone binding capacity |
| US4468469A (en) * | 1981-11-04 | 1984-08-28 | Miles Laboratories, Inc. | Substituted phenylacetic acids and salts as TBP blocking agents in iodothyronine immunoassays |
| US4431741A (en) * | 1981-12-17 | 1984-02-14 | Baxter Travenol Laboratories, Inc. | Hypothyroid control serum |
| US4622293A (en) * | 1983-07-05 | 1986-11-11 | Miles Laboratories, Inc. | Iodothyronine immunoassays employing HMS as TBP blocking agent |
| GB8404843D0 (en) * | 1984-02-24 | 1984-03-28 | Amersham Int Plc | Free analyte assay |
| DE3600365A1 (de) * | 1986-01-09 | 1987-07-16 | Hoechst Ag | Neue thyroninderivate |
| MC2260A1 (fr) * | 1990-06-18 | 1993-04-26 | Dow Chemical Co | Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation |
| US5352803A (en) * | 1992-03-30 | 1994-10-04 | Abbott Laboratories | 5(6)-methyl substituted fluorescein derivatives |
| EP0649533B1 (en) * | 1992-03-30 | 2000-05-10 | Abbott Laboratories | Reagents and methods for the detection and quantification of thyroxine in fluid samples |
| IT1254858B (it) * | 1992-04-14 | 1995-10-11 | Metodo per la determinazione della frazione libera di sostanze presenti nei fluidi biologici. | |
| WO1998003876A1 (en) * | 1996-07-18 | 1998-01-29 | Behringwerke Aktiengesellschaft | Reagents for assays for mycophenolic acid |
| US6171801B1 (en) | 1996-07-18 | 2001-01-09 | Dade Behring Marburg Gmbh | Methods for releasing a ligand from a complex |
| WO2002025288A2 (en) * | 2000-09-22 | 2002-03-28 | Clontech Laboratories Inc. | Highly sensitive proteomic analysis methods and kits and systems for practicing the same |
| JP5465758B2 (ja) * | 2011-09-26 | 2014-04-09 | 富士フイルム株式会社 | 蛍光粒子を用いたサイロキシン免疫アッセイ |
| DE102023108022A1 (de) | 2023-03-29 | 2024-10-02 | Forschungszentrum Jülich GmbH | Neuer L-Thyroxin-Radioiodmarker und Verfahren zu seiner Herstellung |
| JP2024163798A (ja) * | 2023-05-12 | 2024-11-22 | 公益財団法人かずさＤｎａ研究所 | 甲状腺ホルモンの分析方法、分析システム、および、検出システム |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3507618A (en) * | 1964-11-27 | 1970-04-21 | Squibb & Sons Inc | Apparatus and method for determining thyroid function |
| US3714344A (en) * | 1969-05-01 | 1973-01-30 | Mallinckrodt Chemical Works | Method for determining thyroxine in blood serum and reagent therefor |
| US3673183A (en) * | 1969-11-17 | 1972-06-27 | Squibb & Sons Inc | {60 -ureidocephalosporanic acid compounds |
| US3711247A (en) * | 1970-03-02 | 1973-01-16 | Curtis Nuclear Corp | Method for determination of thyro-binding capacity of blood proteins |
| US3928553A (en) * | 1972-03-23 | 1975-12-23 | Univ New York | Radioimmunoassay method for triiodothyronine and thyroxine |
| US3911096A (en) * | 1972-06-23 | 1975-10-07 | Professional Staff Ass Of The | Radioimmunoassay for measurement of thyroxine (T{HD 4{B ) and triiodothyonine (T{HD 3{B ) in blood serum |
-
1976
- 1976-05-21 US US05/688,634 patent/US4111656A/en not_active Expired - Lifetime
- 1976-05-21 NL NL7605447A patent/NL7605447A/xx unknown
- 1976-05-21 CA CA253,155A patent/CA1050425A/en not_active Expired
- 1976-05-26 AU AU14308/76A patent/AU500821B2/en not_active Expired
- 1976-05-31 BR BR3472/76A patent/BR7603472A/pt unknown
- 1976-06-18 DE DE19762627455 patent/DE2627455A1/de active Pending
- 1976-06-23 GB GB26144/76A patent/GB1499958A/en not_active Expired
- 1976-06-25 DD DD193583A patent/DD125022A5/xx unknown
- 1976-06-25 JP JP51074595A patent/JPS584782B2/ja not_active Expired
- 1976-06-25 FR FR7619482A patent/FR2317655A1/fr not_active Withdrawn
- 1976-06-28 BE BE168369A patent/BE843484A/xx unknown
- 1976-08-11 US US05/713,447 patent/US4110076A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU500821B2 (en) | 1979-05-31 |
| FR2317655A1 (fr) | 1977-02-04 |
| JPS523820A (en) | 1977-01-12 |
| JPS584782B2 (ja) | 1983-01-27 |
| BE843484A (fr) | 1976-10-18 |
| GB1499958A (en) | 1978-02-01 |
| US4110076A (en) | 1978-08-29 |
| BR7603472A (pt) | 1977-01-04 |
| DE2627455A1 (de) | 1977-01-13 |
| US4111656A (en) | 1978-09-05 |
| NL7605447A (nl) | 1976-12-28 |
| DD125022A5 (enExample) | 1977-03-23 |
| AU1430876A (en) | 1977-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1050425A (en) | Radioimmunoassay methods for the determination of l-triiodothyronine and thyroxine | |
| US4366143A (en) | Assay for the free portion of substances in biological fluids | |
| EP0082636B2 (en) | Luminescent labelling materials and procedures | |
| US4185084A (en) | Immunochemical measuring method using second antigenic substance | |
| US4034074A (en) | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) | |
| US4672028A (en) | Compositions and method for simultaneous multiple array of analytes using radioisotope chelate labels | |
| US4108974A (en) | Radioimmunoassay for thyroid hormone | |
| CA1079633A (en) | Method for solid phase immunological assay of antigens | |
| US4196185A (en) | Immunoassay for phencyclidine | |
| US4207307A (en) | Simultaneous immunoassay of multiple antigens and assay for cocaine metabolites | |
| US4088746A (en) | Radioimmunoassay for thyroid-stimulating hormone (TSH) | |
| US4235864A (en) | Simultaneous radio immunoassay of multiple antigens and _assay for cocaine metabolites | |
| Dighe et al. | The development of antisera to prostaglandins B2 and F2alpha and their analysis using solid-phase and double antibody radioimmunoassay methods | |
| US4018883A (en) | Thyroxine (T4) radioimmunoassay | |
| Miles | Properties, variants, and applications of the immunoradiometric assay method | |
| Hüfner et al. | A comparison of different compounds for TBG-blocking used in radioimmunoassay for tri-iodothyronine | |
| PATEL et al. | A simplified radioimmunoassay for triiodothyronine | |
| US4438207A (en) | Radioimmunoassay for cannabinoids | |
| US4069305A (en) | I125 Imidazole steroid derivatives | |
| US4052504A (en) | Assay for thyroxine binding globulin | |
| US4341755A (en) | Parathyroid radioimmunoassay | |
| Rehfeld et al. | Radioimmunoassay for gastrin employing immunosorbent | |
| Midgley Jr et al. | [16] Use of the double-antibody method to separate antibody bound from free ligand in radioimmunoassay | |
| US4096237A (en) | Immunoassay for β-endorphin | |
| US4066410A (en) | Thyroid hormone assay |